MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
MESOBLAST LTD
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Aug 27, 2026
$11.95−1.33 (-10.02%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.12 (−29.99%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
MESOBLAST LTD grew revenue 191.4% to $17.20M over fiscal 2025. Free cash flow was -$50.63M.
Revenue
$17.20M
+191.4% vs. a year earlier
Free cash flow
-$50.63M
FY2025
EPS, diluted
-$0.08
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $17.20M
- Net income
- -$102.14M
- EPS, diluted
- -$0.08
- Free cash flow
- -$50.63M
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Revenue
$17.20M+191.4% YoY
Gross profit
$12.07M+104.5% YoY
Net income
-$102.14M
EPS, diluted
-$0.08
Free cash flow
-$50.63M
Reported period